Pharmafit Provence
PASSEDYL Sirop enfant nourrisson Fl/125ml

Urgo Healthcare

PASSEDYL Sirop enfant nourrisson Fl/125ml

CIP / EAN code: 3400934110405

Product information from VIDAL.

Read the product information

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
SmPC of the 08/06/2026

PASSEDYL CHILDREN AND INFANTS, syrup


Forms and presentations

Syrup.


Composition

Sulfoguaiacol................................................................................................................................................ 1,174 g

Sodium benzoate...................................................................................................................................2,268 g

For 100 mL of syrup.

Excipients with known effect: sodium methyl parahydroxybenzoate (E219) (6,3 mg per 5 mL dose), sucrose (3,1 g per 5 mL dose), ethanol (150 mg per 5 mL dose), propylene glycol (E1520).


Excipients:

Tincture of Grindelia, concentrated extract for Tolu syrup, concentrated extract for Polygala syrup, natural orange flower flavouring*, sodium methyl parahydroxybenzoate (E219), caramel flavouring**, citric acid monohydrate, sucrose solution, purified water.

*Composition of the natural orange flower flavouring : Neroli essential oil, orange flower water, ethanol, linalool.

**Composition of caramel flavouring : flavouring preparations, flavouring substances, natural flavouring substances, propylene glycol (E1520), ethanol.



Indications

Adjunctive treatment of bronchial secretion disorders.



Dosage and administration

Oral use.

Infant and child under 5 years: 1 oral syringe filled up to the 5 mL graduation mark, 2 to 3 times a day.

Child over 5 years: 1 oral syringe filled up to the 5 mL graduation mark, 3 to 5 times a day.



Contraindications

History of hypersensitivity to any of the constituents (in particular to sodium benzoate, sodium methyl parahydroxybenzoate (E219).



Warnings and precautions

Special warnings

In case of greasy, purulent expectoration, in case of fever or in case of chronic bronchial and lung disease, re-examine the clinical situation.

Productive coughs, which are a fundamental element of bronchopulmonary defence, should be preserved.

The combination of bronchial mucomodifiers with antitussives and/or secretion-drying substances (antimuscarinics) is irrational.

The indication does not justify prolonged treatment.

Precautions for use

Caution is recommended in subjects with gastroduodenal ulcer.

This medicine contains sodium methyl parahydroxybenzoate (E219) which may cause allergic reactions (possibly delayed).

This medicine contains 3,1 g of sucrose per 5 mL of syrup. This should be taken into account for patients with diabetes mellitus.

Patients with fructose intolerance, glucose-galactose malabsorption syndrome or sucrase/isomaltase deficiency (rare hereditary diseases) must not take this medicine.

This medicine contains 150 mg of alcohol (ethanol) per 5 mL of syrup. The amount in 5 mL of this medicine is equivalent to 4 mL of beer or 2 mL of wine.

A dose of 5 taken of 5 mL of this medicine administered to a child over 5 years weighing 20 kg would result in an exposure to 37,5 mg/kg of ethanol likely to cause an increase in blood alcohol of about 2 mg/100 mL. For comparison, for an adult drinking a glass of wine or 500 mL of beer, the blood alcohol level should be about 50 mg/100 mL.

Co-administration of medicines containing, for example, propylene glycol or ethanol may lead to accumulation of ethanol and induce adverse effects, particularly in young children with low or immature metabolic capacity.



Interactions

The data available to date do not suggest the existence of clinically significant interactions.



Fertility, pregnancy and breastfeeding

Use with caution in pregnant or breastfeeding women, due to a lack of usable clinical data.



Driving and using machines

No effect on the ability to drive vehicles or use machines has been observed.



Adverse effects

Possibility of digestive disorders (nausea, vomiting).

Hypersensitivity reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Centres of Pharmacovigilance - Website: https://signalement.social-sante.gouv.fr/.



Pharmacodynamics

Pharmacotherapeutic class: expectorants, ATC code: R: respiratory system.



Shelf life

3 years.



Special storage precautions

Store below 25°C.



SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

To open the bottle,  Press firmly on the sides of the cap while turning it.

The vial must be closed again after each use.

The dose to be administered for one intake is obtained by pulling the plunger up to the 5 mL graduation. The dose is read at the flange of the syringe.

The use of the syringe for oral administration is strictly reserved for administering PASSEDYL CHILDREN AND INFANTS syrup.

The oral syringe must be rinsed after each use. Do not let it soak in the bottle.



Prescription, supply and reimbursement

Marketing authorisation (AMM)
CIP 3400934110405 (Fl/125ml).
Not reimbursed by Social Security.

Urgo Healthcare
12 RUE DAUPHINE
21000 DIJON
Tel: 03 80 54 50 00 https://urgo.fr/

Source: VIDAL · Updated on 11/11/2026. This information does not replace advice from a healthcare professional.